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Abstract
Objective—To assess the perceptions of eye care providers regarding the clinical management of 
dry eye.
Methods—Invitations to complete a 17-question online survey were mailed to 400 members of 
the North Carolina Ophthalmology and Optometry Associations including community 
optometrists, comprehensive ophthalmologists, and cornea specialists.
Results—The survey was completed by 100 eye care providers (25% response rate). Providers 
reported burning (46.5%) as the most frequent symptom described by patients, followed by 
foreign body sensation (30.3%) and tearing (17.2%). Most respondents (80.8%) listed artificial 
tears as the recommended first-line treatment, even though providers reported high failure rates for 
both artificial tears and cyclosporine A (Restasis). Rheumatoid arthritis, Sjögren syndrome, 
affective disorders such as anxiety and depression, history of photorefractive surgery, smoking, 
and thyroid disease were acknowledged as common comorbid conditions.
Conclusions—The survey provided an informative snapshot into the preferences of eye care 
providers concerning the diagnosis and management of dry eye disease. Overall, burning was the 
most common symptom reported by patients. Providers relied more on patient history in guiding 
their clinical decisions than objective signs. The survey underscores the incongruence when 
comparing subjective symptoms with objective signs, thereby highlighting the urgent need for the 
development of reliable metrics to better quantify dry eye symptoms and also the development of 
a more sensitive and specific test that can be used as the gold standard to diagnose dry eye.
© 2014 Contact Lens Association of Ophthalmologists
Address correspondence to Richard M. Davis, M.D., Department of Ophthalmology, University of North Carolina, 5151 
Bioinformatics, CB 7040, Chapel Hill, NC 27599-7040; richard_davis@med.unc.edu. 
The authors have no funding or conflicts of interest to disclose.
HHS Public Access
Author manuscript
Eye Contact Lens. Author manuscript; available in PMC 2015 May 21.
Published in final edited form as:














Dry eye; Keratoconjunctivitis sicca; Tear osmolarity; Diagnostic tests; Survey; Treatment 
strategies
Epidemiologic studies reveal that dry eye disease (DED), or keratoconjunctivitis sicca, has a 
prevalence ranging from 7.8% to 14.6% in the United States. It affects approximately 4.91 
million Americans aged 50 years and older, although the exact prevalence is unknown 
because of the variance in the definition of the disease.1 The challenge that eye care 
providers face is the complexity of managing DED without a discreet laboratory measure by 
which to monitor the disease status, such as glycated hemoglobin used as a surrogate for 
diabetes control. The report from the 2007 International Dry Eye Workshop (DEWS) 
summarizes this dilemma stating that even when clinical tests are evaluated for efficacy, the 
study populations may have been affected by significant bias because there is no widely 
accepted gold standard for diagnosis.2 The 2011 American Academy of Ophthalmology 
(AAO) Preferred Practice Patterns (PPP) publication on DED states that the epidemiological 
evidence is limited by the lack of uniformity in the definition of dry eye and the inability of 
any single diagnostic test or set of diagnostic tests to confirm or rule out the condition.3 
Moreover, many of the available tests have low repeatability and do not correlate well with 
patient-reported symptoms.1 Alternatively, patient-reported symptoms have been shown to 
have greater repeatability than objective tests,4 and clinically, symptoms may be considered 
the best method for following this condition over time.1
Multiple questionnaires, including the Ocular Surface Disease Index (OSDI), McMonnies 
dry eye index, and the Impact of Dry Eye on Everyday Life (IDEEL), have been developed 
over time to assess and better stratify DED symptom severity. The OSDI is a 12-item survey 
that assesses ocular discomfort and effect of DED on daily life over a 1-week period.5 The 
McMonnies questionnaire is a 12-item instrument that queries not only symptoms but also 
risk factors associated with DED, such as thyroid disease and medicamentosa.6,7 The 
IDEEL, which has 57 questions, was created as a patient-reported outcome measure for 
assessing the impact of DED on daily lives of the patients.8 Although this is certainly not an 
exhaustive list of symptom questionnaires, in general, the aforementioned questionnaires 
and others have shown only moderate correlation with clinical signs. Even when an 
association has been proven, it is usually not possible to predict severity of symptoms based 
on objective signs and vice versa.9 With the potential for great variability in clinical practice 
and the complexity of DED management, this survey was created as a litmus to assess the 
attitudes, perceptions, and current dry eye practice patterns of eye care providers in North 
Carolina. The goal of this survey was not to contribute to the development of a standardized 
set of treatment guidelines, rather, it was meant to generate insight on how eye care 
providers are treating DED as compared with the recommendations set forth by the 2007 
DEWS report and the AAO Dry Eye PPP publication.
Materials and Methods
An anonymous, 17-question online survey was created using SurveyMonkey, a Web-based 
survey engine. Survey items were written to assess practitioner knowledge and opinions on 
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patient symptoms and diagnostic and treatment approaches for patients with DED. Selected 
examples of questions included
“What are the most common symptoms you hear from dry eye patients?”
“What is your first line treatment for dry eye disease?”
“From your experience, what percent of dry eye patients fail treatment with 
artificial tears?”
“From your experience, what percent of dry eye patients fail treatment with 
Restasis?”
“What is the main test you use to guide therapeutic effect?”
“On average, how much time do you spend examining dry eye patients?”
After approval from the University of North Carolina Institutional Review Board, the 
publicly available membership lists of the North Carolina Ophthalmology and Optometry 
Associations were accessed to gain contact information. A total of 400 members, including 
comprehensive ophthalmologists, cornea specialists, and optometrists, were selected from 
the databases. We searched the Optometry and Ophthalmology Academy directories for 
practitioners in North Carolina and systematically selected every third optometrist in the 
optometric directory. Because there were fewer ophthalmologists compared with 
optometrists in the state, all ophthalmologists listed as comprehensive practitioners or 
cornea specialists were selected to participate in the study. Each was mailed an introductory 
letter with a link to the online survey. Descriptive results are presented with no intention to 
infer to any larger population.
Results
Of the 400 mailed letters, 107 providers accessed the online survey. One hundred completed 
the study, yielding a 25% final response rate. Responses to individual questions varied from 
95 to 100 providers. The survey results are summarized in Table 1. Because multiple 
questions were asked in a paired format, where the first item prompted the respondent to 
select the single best answer and the subsequent question gave the respondent the ability to 
select multiple answers to a similar stem, we were able to assess concurrence of responses 
across questions. For the 3 questions asked in this format, 90% to 92% of the respondents 
included their response to the first question as one of their answers to the second item. This 
indicates reasonable consistency among the respondents.
More notable results presented in Table 1 are highlighted. Forty-seven percent of survey 
participants reported tear breakup time (TBUT) as the test they most often used to evaluate 
DED, with fluorescein stain for corneal epithelial defects closely second at 39%. The most 
common combination of tests was TBUT, fluorescein stain, and lissamine green stain. 
Providers reported that the most frequent symptom described by patients with DED was 
burning (46.5%). This was followed by foreign body sensation (30.3%) and tearing 
(17.2%). Itching, inability to cry, and inability to work were rarely reported as common 
symptoms described by dry eye patients. Providers indicated that their first-line therapy for 
DED was artificial tears (80.8%), with warm compresses/lid scrubs closely second (15.2%). 
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Providers were also asked to estimate, based on their clinical experience, what percentage of 
DED patients failed treatment with artificial tears. The most frequent response, selected by 
39.4% of respondents, was that 20% to 40% of their patients failed treatment, whereas 
34.3% of practitioners reported that 40% to 60% of their patients failed treatment. 
Consistent with the product literature, 32.6% of respondents indicated that up to 20% of 
their patients failed cyclosporine ophthalmic emulsion (Restasis 0.05%; Allergan, Inc., 
Irvine, CA). Interestingly, 68.4% of respondents replied that cyclosporine failed in 20% of 
their patients or more. When asked which test was used to guide therapeutic effect, 69.7% 
reported patient history as having the largest impact on their choice of therapies. The most 
common aggregate tests for judging therapeutic effect were patient history (82.8%), 
fluorescein stain (80.8%), TBUT (67.7%), and lissamine green stain (31.3%). When asked 
about the amount of time involved in patient visits, 56.6% of providers reported that they 
spend 4 to 9 minutes examining patients and 69.4% reported that they spend 4 to 9 minutes 
talking with patients in the office. Of note, 68.8% of respondents did not consider 
themselves to be DED specialists. Finally, based on the responses of these providers, 
rheumatoid arthritis, Sjögren syndrome, anxiety or depression, vision correction surgery, 
smoking, and thyroid disease were all considered common comorbidities with response rates 
equal to or greater than 20%.
Discussion
Although the anonymity of the respondents was preserved, much information can be gained 
from the answers of the respondents to the survey. Most respondents (68.8%) identified 
themselves as not being DED specialists. This is consistent with most general or 
comprehensive eye care providers who are likely to encounter and treat patients with DED. 
We did not specify a definition of DED specialist; thus, responses to this question were 
based on the respondent's perception of a specialist. Therefore, the survey gives an 
informative snapshot of how dry eye is being managed in a broader community context 
across both optometrists and ophthalmologists. It should be noted that this survey pooled 
results from comprehensive ophthalmologists, corneal specialists, and optometrists to 
achieve a more meaningful sample size; we did not ask respondents to identify their type of 
training. This approach also provides a stronger reflection of the current standard of care 
among community providers. We justify this approach because previous studies have found 
minor differences in the tests ophthalmologists and optometrists prefer to diagnose dry eye. 
We deemed our pooled method acceptable because there is no other evidence to suggest that 
the three types of providers approach management and treatment of DED differently.
This survey sheds light on the signs and symptoms regularly used by eye care providers to 
guide their diagnosis and treatment. The DEWS group and the AAO PPP made 
recommendations for diagnosing dry eye, and this survey provides the opportunity to 
compare how such recommendations are practiced in the community. Although TBUT and 
fluorescein stain were the most frequently used clinical tests, 69.7% of respondents relied on 
patient history as the most common measure of therapeutic effect. Such findings suggest less 
reliance on any of the objective tests available at present. Our results are corroborated by 
two previous studies. In another survey study published by Korb10 in 2000, 68 
ophthalmologists and optometrists (34 of each) replied with their top choices for diagnostic 
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tests. Although patient history was the most common overall first choice by respondents, 
fluorescein breakup time and history were the most popular for optometrists, whereas 
ophthalmologists were much more likely to rank Schirmer testing as the most important 
diagnostic test.10 In that same year, Nichols et al.11 published a multisetting record review 
examining this same topic. They likewise found that history was the most commonly used 
clinic tool, although optometrists once again preferred staining and TBUT to the Schirmer 
testing and tear meniscus assessment used by ophthalmologists. Our study, performed over a 
decade later, shows a preference for TBUT and fluorescein stain. This may indicate that a 
higher proportion of optometrists responded to our survey; however, we are unable to 
directly test this hypothesis because we did not separate responses based on provider type. 
Despite the development of other diagnostics in the past 10 years, none of them have 
supplanted patient history as the leading test for the diagnosis of DED.
Neither of the earlier studies by Nichols et al.11 and Korb,10 published before the release of 
the DEWS report, had appreciable response rates for tear osmolarity. The 2003 version of 
the AAO PPP does not discuss tear osmolarity for the diagnosis of DED,12 but tear 
osmolarity is mentioned in the 2011 revision of this publication.3 Although the DEWS 
group recognized tear osmolarity as a well-validated measure with the potential to become 
the gold standard for diagnosing DED, the group also cautioned that the technology is not 
widely in use outside of research settings and academic institutions.2 Our survey 
corroborates this, with only 2% of providers reporting tear osmolarity as a frequently used 
objective test to evaluate dry eye. Because technology for assessing tear osmolarity has only 
recently become available, the low amount of responses for this test suggests that many 
providers have not yet adopted this modality for in-office diagnosis. The alternative DEWS 
recommendation for first-line diagnosis is TBUT, which, in our survey, was shown to be the 
most commonly used test.2
According to our survey, providers selected burning and foreign body sensation among the 
available choices as the symptoms they most often hear from patients with dry eye. As noted 
earlier, patient symptom questionnaires, such as the OSDI, are now frequently used, at least 
in a research context, as standardized measures of patient-reported symptoms. Interestingly, 
the most common symptom reported by respondents was eye burning, but this symptom is 
not included in the OSDI, nor does this questionnaire specifically ask about the next two 
most frequently reported symptoms: foreign body sensation (although OSDI does ask about 
gritty eyes) and tearing.5 The McMonnies questionnaire does ask about burning and 
grittiness but not tearing.6 However, one of the flaws of the available questionnaires is that 
patients are confined to selecting symptoms from multiple-choice answers, thereby limiting 
their ability to fully describe their symptoms. There may be a need for a more patient-
centered, self-reported measure or questionnaire for clinical practice, which allows patients 
to report their experience with the symptoms that are most bothersome to them, rather than 
merely selecting symptoms from a list.
In addition, the currently available medical agents for the treatment of DED, artificial tears 
and cyclosporine, demonstrated significant failure rates in the experience of our respondents. 
Although artificial tears were the first-line treatment for 80.8% of the providers, 85.9% of 
providers identified a failure rate of 20% or more for such agents. Studies have 
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demonstrated improvement in clinical signs with artificial tears, but at a practice level, 
providers still reported that large numbers of patients failed with this therapy.13 Providers 
were also asked about the cyclosporine failure rate, with “failure” serving as a broad term 
encompassing both intolerance to the medication and the lack of efficacy in relieving ocular 
symptoms. In phase-3 clinical trials, 6.5% of the participants randomized to 0.05% 
cyclosporine prematurely discontinued the drug owing to adverse side effects.14 A 2008 
study by Perry et al.15 evaluating cyclosporine in mild, moderate, and severe DED reported 
that 9.4% of 158 patients failed to complete 3 months of treatment because of adverse 
effects, lack of positive effect, or expense in continuing therapy, with burning on 
application as the most common reason for treatment failure (4.4% of all patients). 
According to information from the manufacturer of cyclosporine ophthalmic emulsion, the 
most common adverse event with this drug is burning, which is experienced in 17% of 
patients.16 In the phase-3 trials, 31.5% of patients using 0.05% cyclosporine ophthalmic 
emulsion showed no improvement based on the physicians' global response to treatment 
assessment,14 whereas in the study by Perry et al,15 22% of patients reported no 
improvement in symptoms, and 6.67% actually reported worsening of symptoms. In the 
experience of the providers in this survey, the cyclosporine failure rate was most frequently 
estimated to be 0% to 20%, indicating that treatment was successful in 80% to 100% of 
patients. However, it is interesting to note that an aggregate of 68.4% of respondents chose a 
failure rate of 20% or greater. In addition, 4.2% of respondents indicated that patients failed 
cyclosporine at least 80% of the time. These responses serve as further confirmation that 
medical therapies, such as artificial tears and cyclosporine, have significant failure rates, 
even though they are commonly recommended as therapy for DED. The result exemplifies 
the need for continued research to develop specific drug targets to treat DED.
The survey also asked providers to indicate which comorbidities they most often see in their 
dry eye patients. Rheumatoid arthritis, Sjögren syndrome, anxiety or depression, vision 
correction surgery, smoking, and thyroid disease all received 29% of responses or greater. 
This was consistent with the Beaver Dam and Blue Mountains Eye studies, and a Taiwanese 
report, which indicated that all of the aforementioned conditions have a higher prevalence in 
patients with DED.17–19 The increased prevalence of anxiety and/or depression among dry 
eye patients is consistent with the numbers reported in other chronic diseases. Up to 20% of 
patients with diabetes and coronary heart disease, for example, also reportedly have 
depression.20 This underscores the need for more investigation into the relationship between 
depression and DED and the possibility of using chronic disease management strategies in 
DED.
The limitations of this study are its moderate response rate and small sample size. In 
addition, only North Carolina providers were surveyed, limiting generalizability to the 
broader U.S. population. Furthermore, because this survey was presented in a multiple-
choice format, respondents were forced to select one of the available answers and could not 
provide their own response. This limited the ability to assess individual preferences in 
diagnosing and managing DED. In several of the survey items, we asked providers to 
respond to questions about the failure rate of treatments, such as artificial tears and 
cyclosporine; questioning about the failure rate instead of the success rate may have 
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introduced a negative bias. Finally, no questions addressed contact lens wear as a contributor 
to DED.
In conclusion, although multiple studies have evaluated clinical tests and symptoms of dry 
eye, no gold standard currently exists for unequivocal diagnosis of DED.3 In our 
respondents, patient history was widely reported as the most commonly used factor to guide 
DED management, with TBUT as the most commonly used objective test. Overall, this 
survey shows that current practice patterns largely reflect the recommendations in the 
DEWS report and AAO PPP document. However, adoption of tear osmolarity in particular 
has lagged behind the implementation of some other objective tests, which may be a 
reflection of financial barrier to using this technology. An alternative explanation may be 
that providers prefer patients' self-report over tear osmolarity testing. The lack of tear 
osmolarity adoption requires further study. Given the emphasis on patient history and 
limitations of currently available symptom questionnaires mentioned above, more work is 
needed to identify a practical measure of patient-reported symptoms because they relate to 
the quality of life. Finally, this survey reiterates the urgent need for more effective 
diagnostic and therapeutic modalities, given the respondents' preference for patient history 
and the reported high failure rates for both artificial tears and cyclosporine.
Acknowledgments
J. F. Williamson had full access to all the data in the study and takes responsibility for the integrity of the data and 
the accuracy of the data analysis.
References
1. Smith JA, Albeitz J, Begley C, et al. The epidemiology of dry eye disease: Report of the 
epidemiology subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007; 5:93–
107. [PubMed: 17508117] 
2. Bron AJ, Abelson MB, Ousler G, et al. Methodologies to diagnose and monitor dry eye disease: 
Report of the diagnostic methodology subcommittee of the International Dry Eye Workshop (2007). 
Ocul Surf. 2007; 5:108–152. [PubMed: 17508118] 
3. Feder, RS., editor. Dry Eye Syndrome— Limited Revision. San Francisco, CA: America Academy 
of Ophthalmology; 2011. American Academy of Ophthalmology Cornea/External Disease Panel. 
Preferred practice pattern guidelines. Available at: www.aao.org/ppp [Accessed April 10, 2012]
4. Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea. 
2004; 23:272–285. [PubMed: 15084861] 
5. Ozcura F, Aydin S, Helvaci MR. Ocular Surface Disease Index for the diagnosis of dry eye 
syndrome. Ocul Immunol Inflamm. 2007; 15:389–393. [PubMed: 17972223] 
6. McMonnies CW. Key questions in a dry eye history. J Am Optom Assoc. 1986; 57:512–517. 
[PubMed: 3489027] 
7. Nichols KK, Nichols JJ, Mitchell GL. The reliability and validity of McMonnies Dry Eye Index. 
Cornea. 2004; 23:365–371. [PubMed: 15097131] 
8. Abetz L, Rajagopalan K, Mertzanis P, et al. Development and validation of the impact of dry eye on 
everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the 
assessment of the burden of dry eye on patients. Health Qual Life Outcomes. 2011; 9:111. 
[PubMed: 22152125] 
9. Johnson ME. The association between symptoms of discomfort and signs in dry eye. Ocul Surf. 
2009; 7:199–211. [PubMed: 19948103] 
10. Korb DR. Survey of preferred tests for diagnosis of the tear film and dry eye. Cornea. 2000; 
19:483–486. [PubMed: 10928763] 
Williamson et al. Page 7













11. Nichols KK, Nichols JJ, Zadnik K. Frequency of dry eye diagnostic test procedures used in various 
modes of ophthalmic practice. Cornea. 2000; 19:477–482. [PubMed: 10928762] 
12. Matoba, AY., editor. Dry Eye Syndrome— Limited Revision. San Francisco, CA: America 
Academy of Ophthalmology; 2003. American Academy of Ophthalmology Cornea/External 
Disease Panel. Preferred practice pattern guidelines. Available at: www.aao.org/ppp [Accessed 
April 10, 2012]
13. Doughty MJ, Glavin S. Efficacy of different dry eye treatments with artificial tears or ocular 
lubricants: A systematic review. Ophthalmic Physiol Opt. 2009; 29:573–583. [PubMed: 
19686307] 
14. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and 
safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. 
Ophthalmology. 2000; 107:631–639. [PubMed: 10768324] 
15. Perry HD, Solomon R, Donnenfield ED, et al. Evaluation of topical cyclosporine for the treatment 
of dry eye disease. Arch Ophthalmol. 2008; 126:1046–1050. [PubMed: 18695097] 
16. Allergan. [Accessed September 20, 2013] Restasis Prescribing Information. 2013. Available at: 
http://www.allergan.com/assets/pdf/restasis_pi.pdf
17. Wang TJ, Wang IJ, Hu CC, et al. Comorbidities of dry eye disease: A nationwide population-based 
study. Acta Ophthalmol. 2012; 90:663–668. [PubMed: 20809911] 
18. Chia EM, Mitchell P, Rochtchina E, et al. Prevalence and associations of dry eye syndrome in an 
older population: The Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2003; 31:229–
232. [PubMed: 12786773] 
19. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch 
Ophthalmol. 2000; 118:1264–1268. [PubMed: 10980773] 
20. Katon W, Lin E, Von Korff M, et al. Integrating depression and chronic disease care among 
patients with diabetes and/or coronary heart disease: The design of the TEAMcare study. Contemp 
Clin Trials. 2010; 31:312–322. [PubMed: 20350619] 
Williamson et al. Page 8

























Williamson et al. Page 9
Table 1
Results of Dry Eye Disease Survey Completed by Ophthalmologists and Optometrists
Question Number Question Respondents, n (%)
1 What is your most often used test to evaluate dry eye disease? 100
 Schirmer test with anesthetic 3 (3.0)
 Schirmer test without anesthetic 2 (2.0)
 Tear breakup time 47 (47.0)
 Tear osmolarity 2 (2.0)
 Fluorescein stain 39 (39.0)
 Lissamine green stain 7 (7.0)
2 Which of the following tests do you most often use to evaluate dry eye disease?a 100
 Schirmer test with anesthetic 25 (25.0)
 Schirmer test without anesthetic 11 (11.0)
 Tear breakup time 83 (83.0)
 Tear osmolarity 4 (4.0)
 Fluorescein stain 77 (77.0)
 Lissamine green stain 28 (28.0)
3 What is the most common symptom you hear from dry eye disease patients? 99
 Burning 46 (46.5)
 Itching 4 (4.0)
 Foreign body sensation 30 (30.3)
 Tearing 17 (17.2)
 Inability to cry 1 (1.0)
 Inability to work 1 (1.0)
4 What are the most common symptoms you hear from dry eye patients?a 99
 Burning 85 (85.9)
 Itching 30 (30.3)
 Foreign body sensation 74 (74.7)
 Tearing 77 (77.8)
 Inability to cry 4 (4.0)
 Inability to work 9 (9.1)
5 What is your first-line treatment of dry eye disease? 99
 Artificial tears 80 (80.8)
 Restasis 1 (1.0)
 Fish oil supplements 3 (3.0)
 Punctal occlusion 0 (0)
 Warm compresses and lid scrubs 15 (15.2)
6 From your experience, what percent of dry eye disease patients fail treatment with artificial tears? 99
 Up to 20% 14 (14.1)
 20%–40% 39 (39.4)
 40%–60% 34 (34.3)
 60%–80% 10 (10.1)
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Question Number Question Respondents, n (%)
 80%–100% 2 (2.0)
7 From your experience, what percentage of dry eye disease patients fail treatment with 
cyclosporine A (Restasis)?
95
 Up to 20% 31 (32.6)
 20%–40% 24 (25.3)
 40%–60% 27 (28.4)
 60%–80% 9 (9.5)
 80%–100% 4 (4.2)
8 What is the main test you use to guide therapeutic effect? 99
 Patient history 69 (69.7)
 Schirmer test 2 (2.0)
 Fluorescein stain 12 (12.1)
 Lissamine green stain 6 (6.1)
 Tear breakup time 9 (9.1)
 Tear osmolarity 1 (1.0)
9 Which of the following tests do you use to guide therapeutic effect?a 99
 Patient history 82 (82.8)
 Schirmer test 19 (19.2)
 Fluorescein stain 80 (80.8)
 Lissamine green stain 31 (31.3)
 Tear breakup time 67 (67.7)
 Tear osmolarity 5 (5.1)
10 On average, how much time do you spend examining dry eye patients? 99
 1–3 min 13 (13.1)
 4–6 min 35 (35.4)
 7–9 min 21 (21.2)
 10–12 min 16 (16.2)
 13–15 min 6 (6.1)
 . 15 min 8 (8.1)
11 On average, how much time do you spend talking with your patients? 98
 4–6 min 33 (33.7)
 7–9 min 35 (35.7)
 10–12 min 20 (20.4)
 13–15 min 4 (4.1)
 . 15 min 6 (6.1)
12 Are you a specialist in the management of dry eye disease? 96
 Yes 30 (31.3)
 No 66 (68.8)
13 Is there one artificial tear you prefer? 97
 Yes 51 (52.6)
 No 46 (47.4)
14 What are the most common comorbid conditions of your dry eye patients?a 99
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Question Number Question Respondents, n (%)
 Rheumatoid arthritis 60 (60.6)
 Sjögren syndrome 49 (49.5)
 Gout 6 (6.1)
 Anxiety or depression 30 (30.3)
 Vision correction surgery 39 (39.4)
 Smoking 41 (41.4)
 Thyroid disease 29 (29.3)
 None of the above 21 (21.2)
15 How long have you been practicing? 99
 , 5 y 12 (12.1)
 5–10 y 12 (12.1)
 10–20 y 21 (21.2)
 20–30 y 31 (31.3)
 30–40 y 17 (17.2)
 . 40 y 12 (12.1)
16 What is your gender? 98
 Female 26 (26.5)
 Male 72 (73.5)
a
Respondents were permitted to select more than one answer on these items, so the percentages may not add to 100%.
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